Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 1

Status

Active not recruiting 5Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 2Neoplasms 1Advanced Solid Tumor 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × berzosertib × Clear all
NCT03309150 2024-11-29

ATRi Transition Rollover Study

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
1 enrolled 4 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05246111 2024-11-22

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
6 enrolled 30 charts

Hereditary Sensory and Autonomic Neuropathies

NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
53 enrolled 20 charts
Tumor-Agnostic

Neoplasms

NCT02157792 2020-04-01

M6620 First in Human Study

EMD Serono

Phase 1 Completed
200 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡